TABLE 2.
Frequency of WBi results with different cohorts from different territories
| Country or region | Cohort | Population total (n) | No. screen positive (no. negative) | No. of WBi results (%) | Reference |
|---|---|---|---|---|---|
| United States | Blood donor | 500,000 | 1,100 | 160 (14.5) | 80 |
| United States | Blood donor | 3,270,000 | 2,660 | 1,207 (45.4) | 27 |
| Peru | General population | 1,363 | 35 | 13 (37.1) | 19 |
| Chile | Donor and risk group | 600,000 | 4,956 | 409 (8.3) | 68 |
| India | Blood donor | 39,784 | 44 | 5 (11.4) | 92 |
| Nigeria | Blood donor | 500 | 186 | 55 (29.6) | 28 |
| Ethiopia | Volunteersa | 12,124 | 1,437 (1,475)c | 91 (6.3)/31 (2.1)c,e | 57 |
| Brazil | Rejected donor | NAb | 210d | 6 (2.9) | 4 |
| Central Africa | High-risk group | 1,998 | 1,065 | 367 (34.5) | 5 |
| United States | High-risk group | NA | 371 | 123 (33.2) | 96 |
| United States | Other disorders | NA | 199 | 73 (36.7) | 96 |
| Saudi Arabia | Hospital/health center cohorts | NA | 2,849 | 444 (15.6) | 39 |
| Brazil | Pregnant women | 9,786 | 105 | 11 (10.5) | 21 |
| Cameroon | Pregnant women | 859 | 163 | 13 (8.0) | 33 |
a
Participants in Ethio-Netherlands AIDS Research Project.
b
NA, not available.
c
Only 1,475 of the 10,687 screened negative were included in Western blot testing.
d
Selected cohort; no association was made with the initial population screened.
e
The two values are number of WBi results among those who screened positive/number of WBi results among those who screened negative, with percentages for each given parenthetically.